The funding gap in women’s health is real

Women’s health tech has exploded with innovation, but the funding that should have followed hasn’t. Despite serving half the global population, femtech startups still fight for scraps. In 2021, women’s health startups captured just 7% of digital health funding. By 2024, that share across all venture capital had fallen to 2.3%. Globally, the picture is even starker—only 5% of health R&D focuses on women’s health, and menopause research represents less than 1% of that tiny fraction.

The problem isn’t just limited funding—it’s the shifting definition of proof. Three years ago, a femtech startup could raise on vision, traction, and testimonials. Investors were satisfied with strong retention, glowing reviews, and DAU growth. Today, investors don’t just ask if women love your product. They ask if it works. Without evidence-based validation, even strong traction can’t sustain momentum.

The End of the “Validate Later” Era

Too many femtech founders still fall into the same trap: building first and validating later. It’s understandable—early-stage teams focus on growth—but when validation becomes an afterthought, it becomes a barrier to scale.

Founders walk into investor meetings showcasing retention and testimonials, but not symptom reduction, functional improvement, or measurable health outcomes. The conversation stalls. Retrofitting science into a product that wasn’t built for measurement drains resources, delays partnerships, and often kills momentum.

In 2025, this isn’t a “nice-to-have” problem—it’s existential. Investors now expect proof pipelines: credible, data-driven plans that show how pilot evidence will evolve into publishable results and payer-ready validation. For femtech, this shift is especially crucial. The category has long been mislabeled as “niche,” but rigorous data reframes that bias and proves that women’s health innovation serves half the population.

When science becomes part of your business model, it changes the investor conversation. You’re not just selling a story—you’re showing a trajectory. Pilot data, measurable outcomes, and aligned endpoints turn promise into investability. In today’s femtech funding environment, evidence is your most valuable growth engine.

How the Ground Shifted

Over the past few years, wellness and digital health have undergone a reckoning. The “growth at all costs” era flooded the market with apps promising to improve stress, sleep, or hormones—often validated only by self-reported surveys. Investors learned the hard way that engagement doesn’t equal effectiveness.

Meanwhile, payers and health systems became far more discerning. “Wellness” is now under scrutiny. They’re asking for measurable proof—functional improvement, cost savings, and validated health outcomes they can defend to their boards.

And as AI accelerates development, product features, UX, and even branding can be replicated overnight. What can’t be copied is evidence—defensible, third-party data proving your product delivers real-world impact. For femtech, that’s not a setback; it’s a competitive advantage. The companies that lead with science are setting a higher standard for what women’s health innovation should look like.

What Counts as Evidence Now

Femtech companies that treat science as a growth strategy move faster through investor diligence, secure enterprise partnerships sooner, and build brands that last. The next generation of leaders in fertility, menopause, and menstrual health won’t rely on aspirational marketing—they’ll lead with data.

Every milestone, from fundraising to expansion, becomes easier when your foundation is measurable, defensible, and aligned with the markets you serve. In a category that’s long been undervalued, early evidence isn’t just a differentiator—it’s what transforms femtech from a sector fighting for recognition into one defining the future of health.

In this context, “evidence” doesn’t mean engagement metrics or testimonials. It means measurable change supported by validated tools that withstand scientific and payer scrutiny—proof of real improvements in symptoms, function, and quality of life. For instance, menopause symptoms can be tracked with the Menopause Rating Scale (MRS), fertility outcomes with the Fertility Quality of Life Tool (FertiQoL), and menstrual health with the Daily Record of Severity of Problems (DRSP). Broader measures like the PHQ-9 and GAD-7 can complement these tools when emotional well-being is part of the outcome story.

Validated outcomes make results meaningful beyond engagement—they demonstrate real improvement, quality-of-life gains, and cost impact that investors, payers, and users all recognize as proof of value.

The High Cost of Weak Science

Without rigorous data, even the most promising femtech startups end up competing on branding, not outcomes. That’s a losing game. You can’t outspend larger players forever, and you can’t build enterprise relationships without proof.

Weak evidence limits growth, traps companies in direct-to-consumer models with high acquisition costs, and prevents payer or employer partnerships. It also invites skepticism—from investors, regulators, and users—at the exact moment you need traction.

By contrast, evidence-based femtech companies build credibility faster. They enter payer conversations earlier, command higher valuations, and attract more durable funding. Evidence isn’t just a signal to investors—it’s feedback that makes your product smarter, your brand more trusted, and your growth sustainable.

Making Science Scalable

Scientific validation doesn’t require a million-dollar clinical trial. It works to start small and early. A lean validation study can be kicked off during your beta phase. The goal isn’t perfection—it’s direction. Collect baseline data from your first 50–100 users using validated tools. Track changes over time. Embed measurement into your product experience.

When you walk into your next investor pitch, you’ll be able to show (not just say) that your product works. Early evidence can help reduce funding timelines and increase valuations, because it replaces uncertainty with data. When that data maps to payer priorities like function, cost, and quality of life, it opens enterprise doors that testimonials never could.

Why This Matters

At Fit Minded, we believe evidence isn’t just a funding strategy—it’s a moral one. Women’s health has been underfunded, understudied, and undervalued for decades. If femtech companies flood the market with unproven claims, we reinforce the very biases we’re trying to overcome.

Science is how we change that story. It’s how we prove that solutions for menopause, fertility, maternal health, and menstrual wellness deserve the same rigor and respect as every other category in medicine.

The companies that understand this—those that build with science, not around it—aren’t just raising capital. They’re redefining what women’s health innovation means.